Jonas, Jost B. http://orcid.org/0000-0003-2972-5227
Zhang, Qi
Xu, Liang
Wei, Wen Bin http://orcid.org/0000-0003-2386-0989
Jonas, Rahul A.
Wang, Ya Xing http://orcid.org/0000-0003-2749-7793
Funding for this research was provided by:
National Natural Science Foundation of China (81570835)
Article History
Received: 9 November 2021
Revised: 31 January 2022
Accepted: 8 February 2022
First Online: 23 February 2022
Change Date: 28 February 2022
Change Type: Update
Change Details: The figures were changed to color figures in pdf.
Competing interests
: JBJ and RAJ: European patent application 16 720 043.5 and US patent application US 2019 0085065 A1: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia). JBJ: Advisory Board Novartis; Patent holder with Biocompatibles UK Ltd. (Farnham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and/or anti-angiogenic factor; Patent number: 20120263794), Patent application: Agents for the use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases. All other authors: None.